Kesatuan Eropah - Jerman - EMA (European Medicines Agency)

sanofi b.v. - thyrotropin alfa - schilddrüsenneoplasmen - vorderen hypophysenlappens hormone und analoga hypophysen-und hypothalamus-hormone und analoga - thyrogen is indicated for use with serum thyroglobulin (tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (thst). low risk patients with well-differentiated thyroid carcinoma who have undetectable serum tg levels on thst and no rh (recombinant human) tsh-stimulated increase of tg levels may be followed-up by assaying rh tsh-stimulated tg levels. thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mci (1. 1 gbq) to 100 mci (3. 7 gbq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.

Kesatuan Eropah - Jerman - EMA (European Medicines Agency)

sanofi b.v. - sevelamer - renal dialysis; hyperphosphatemia - alle anderen therapeutischen produkte - renagel is indicated for the control of hyperphosphataemia in adult patients receiving  haemodialysis or peritoneal dialysis. renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Kesatuan Eropah - Jerman - EMA (European Medicines Agency)

sanofi b.v. - avalglucosidase alfa - glykogenspeicherkrankheit typ ii - anderen verdauungstrakt und stoffwechsel-produkte, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).

Kesatuan Eropah - Jerman - EMA (European Medicines Agency)

sanofi b.v. - olipudase alfa - acid sphingomyelinase deficiency (asmd) type a/b or type b - anderen verdauungstrakt und stoffwechsel-produkte, - xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (cns) manifestations of acid sphingomyelinase deficiency (asmd) in paediatric and adult patients with type a/b or type b.

Jerman - Jerman - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sanofi-aventis deutschland gmbh (8030868) - adenosin - injektionslösung - teil 1 - injektionslösung; adenosin (03304) 6 milligramm

Jerman - Jerman - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sanofi-synthelabo gmbh (3073784) - amisulprid - filmtablette - teil 1 - filmtablette; amisulprid (23671) 400 milligramm

Jerman - Jerman - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sanofi-synthelabo gmbh (3073784) - amisulprid - tablette - teil 1 - tablette; amisulprid (23671) 200 milligramm

Jerman - Jerman - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sanofi-synthelabo gmbh (3073784) - amisulprid - tablette - teil 1 - tablette; amisulprid (23671) 100 milligramm

Jerman - Jerman - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sanofi-aventis deutschland gmbh (8030868) - amiodaronhydrochlorid - injektionslösung - teil 1 - injektionslösung; amiodaronhydrochlorid (21609) 150 milligramm

Jerman - Jerman - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sanofi-aventis deutschland gmbh (8030868) - amiodaronhydrochlorid - tablette - teil 1 - tablette; amiodaronhydrochlorid (21609) 200 milligramm